Christiane Marth - Gynecology

Author Information

Christiane Marth is affiliated with the Department of Obstetrics and Gynecology at the Medical University Innsbruck, located in Innsbruck, Austria. Her research primarily focuses on gynecological oncology, with significant contributions to the understanding and treatment of ovarian and endometrial cancers.

Research Contributions

Christiane Marth has significantly advanced the field of gynecological oncology through numerous high-impact research studies. In 2022, she contributed to understanding the real-world effects of bevacizumab in newly diagnosed epithelial ovarian cancer and evaluated the dubious effects of methadone as an "anticancer" drug on ovarian cancer cell lines. In 2021, she was involved in multiple pivotal Phase 3 trials, including studies on pembrolizumab and lenvatinib for advanced endometrial cancer, pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer, and alpelisib plus olaparib for platinum-resistant high-grade serous ovarian cancer. Additionally, her work extended to the impact of the COVID-19 pandemic on cancer detection rates and various other clinical trials aimed at improving cancer treatment outcomes.

Aliases

Christiane Marth is also known by several aliases, including C. Marth, Ch. Marth, C H Marth, Christian Marth, and Ch Marth.

Publication and Citation Metrics

Metric	Value
Total Papers	645
Total Citations	25,341
H-Index	73

Publications:

Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer

DOI: 10.1007/s00508-022-02005-2

Year: 2022

Dubious effects of methadone as an “anticancer” drug on ovarian cancer cell-lines and patient-derived tumor-spheroids

DOI: 10.1016/j.ygyno.2022.01.008

Year: 2022

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

DOI: 10.1136/ijgc-2021-003017

Year: 2021

EPV036/#142 European network for gynaecological oncological trial (ENGOT)-CX11/gynecologic oncology group (GOG) 3047/keynote-A18: phase 3 trial of pembrolizumab plus chemoradiotherapy in high-risk locally advanced cervical cancer

DOI: 10.1136/ijgc-2021-igcs.104

Year: 2021

261 ENGOT-cx11/GOG 3047/KEYNOTE-A18: phase 3 randomized study of pembrolizumab + chemoradiotherapy for high-risk locally advanced cervical cancer

DOI: 10.1136/ijgc-2021-esgo.21

Year: 2021

EPV279/#351 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline brca mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer

DOI: 10.1136/ijgc-2021-igcs.350

Year: 2021

988 The impact of COVID-19 pandemic on gynecological and breast cancer detection rate: A tertiary center perspective

DOI: 10.1136/ijgc-2021-esgo.323

Year: 2021

ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.

DOI: 10.1200/JCO.2021.39.15_SUPPL.TPS5608

Year: 2021

ENGOT-ov54/Swiss-GO-2/MATAO including LOGOS (Low-Grade Ovarian cancer Sub-study): MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer—A randomized, double-blinded, placebo-controlled, multicenter phase III Trial.

DOI: 10.1200/JCO.2021.39.15_SUPPL.TPS5598

Year: 2021

Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.

DOI: 10.1016/j.ejca.2021.08.023

Year: 2021

How Do Regulations Affect Abortion Services?

How is Menopause Managed?

What is Dysuria?

What is the Ideal pH for Vaginal Soaps?

Why is Compression Used?

What Causes Umbilical Cord Issues?

What are Vascular Conditions in Gynecology?

How Does Biomedical Research Impact Gynecological Oncology?

What Guidelines Should Gynecologists Follow?

What role do healthcare providers play in cost savings?

Partnered Content Networks

Relevant Topics